Osteoarthritis Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2017" report to their offering.

This report provides comprehensive information on the therapeutic development for Osteoarthritis , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects.

The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Osteoarthritis Overview
  3. Therapeutics Development
  4. Pipeline Products for Osteoarthritis - Overview
  5. Pipeline Products for Osteoarthritis - Comparative Analysis
  6. Osteoarthritis - Therapeutics under Development by Companies
  7. Osteoarthritis - Therapeutics under Investigation by Universities/Institutes
  8. Osteoarthritis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Osteoarthritis - Products under Development by Companies
  13. Osteoarthritis - Products under Investigation by Universities/Institutes
  14. Osteoarthritis - Companies Involved in Therapeutics Development
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • Amgen Inc
  • Amura Holdings Ltd
  • Arcarios BV
  • Asahi Kasei Pharma Corp
  • Asklepios BioPharmaceutical Inc
  • Astellas Pharma Inc
  • Evgen Pharma Plc
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Gemphire Therapeutics Inc
  • GeneFrontier Corp
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • Jeil Pharmaceutical Co Ltd
  • Jenrin Discovery Inc
  • K-Stemcell Co Ltd
  • Kang Stem Biotech Co Ltd
  • Levolta Pharmaceuticals Inc
  • NicOx SA
  • Nordic Bioscience A/S
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Omeros Corp
  • Ono Pharmaceutical Co Ltd
  • OrthoCyte Corp
  • Osteologix Holdings Plc
  • Pfizer Inc
  • Pharmalink AB
  • Philogen SpA
  • PhytoHealth Corp
  • PLx Pharma Inc
  • Takeda Pharmaceutical Company Ltd
  • TissueGene Inc

For more information about this report visit http://www.researchandmarkets.com/research/d5scct/osteoarthritis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs